Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.45 |
| ▸ | NTSR2 | O95665 | 10/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 10/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 10/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.43 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946505 | 1.00 | GRB2 (0.47) | GRB2CAPN1NTSR2NTSR1SORT1 | |
| SCHEMBL4946926 | 0.94 | GRB2 (0.49) | GRB2CAPN1CXCL8 | |
| SCHEMBL4946938 | 0.94 | GRB2 (0.49) | GRB2CAPN1CXCL8 | |
| SCHEMBL29575751 | 0.86 | NTSR2 (0.46) | GRB2CAPN1NTSR2NTSR1SORT1 | |
| SCHEMBL29498761 | 0.86 | KMT2A (0.46) | NTSR2NTSR1SORT1 | |
| SCHEMBL29470192 | 0.86 | ACE (0.50) | NTSR2NTSR1SORT1 | |
| SCHEMBL30435240 | 0.85 | NTSR2 (0.46) | GRB2NTSR2NTSR1SORT1 | |
| SCHEMBL30987363 | 0.85 | NMUR2 (0.41) | GRB2CAPN1NTSR2NTSR1SORT1 | |
| SCHEMBL30830432 | 0.84 | FNTA (0.44) | GRB2NTSR2NTSR1SORT1 | |
| SCHEMBL30059762 | 0.84 | SLC6A2 (0.50) | GRB2CAPN1NTSR1NAA50 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470776-B2 | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070167356-A1 | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof | CUMMINGS RICHARD D | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167356-A1 | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof | SIGLEC7, SIGLEC9, SELL | GRB2 321/4885CAPN1 3917/4885NTSR2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.